Surface Oncology Revenue and Competitors

Boston, MA USA

Location

$63.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Surface Oncology's estimated annual revenue is currently $59.4M per year.(i)
  • Surface Oncology received $35.0M in venture funding in January 2015.
  • Surface Oncology's estimated revenue per employee is $1,237,854
  • Surface Oncology's total funding is $63.9M.

Employee Data

  • Surface Oncology has 48 Employees.(i)
  • Surface Oncology grew their employee count by -51% last year.

Surface Oncology's People

NameTitleEmail/Phone
1
SVP, Development OperationsReveal Email/Phone
2
Director, Analytical DevelopmentReveal Email/Phone
3
Director ImmunologyReveal Email/Phone
4
Senior Director, Clinical ScienceReveal Email/Phone
5
HR Associate, Talent Acquisition ManagerReveal Email/Phone
6
Regulatory Operation ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Surface Oncology?

Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients anti-tumor immune response. Our broad attack on the TME has the potential to convert patients non-responsive cold tumors into immune-active ones. We are committed to developing a pipeline of next-generation immunotherapies that deliver lasting benefits to patients suffering from cancer as quickly as possible. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. We utilize multiple antibody generation platforms and have established relationships with several best-in-class antibody technology partners. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment. The company has a strategic collaboration with Novartis and is supported by leading healthcare investors, including Atlas Venture, NEA, F-Prime, Lilly Ventures and Amgen Ventures.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$63.9M

Total Funding

48

Number of Employees

$59.4M

Revenue (est)

-51%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Surface Oncology News

2022-04-20 - Surface Oncology (NASDAQ:SURF) vs. Monte Rosa ...

Surface Oncology (NASDAQ:SURF) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Review. Posted by admin on Apr 25th, 2022.

2022-04-17 - Surface Oncology Named one of the 2022 Best Places to ...

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline...

2022-03-30 - Surface Oncology Reports Inducement Grant under Nasdaq ...

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline...

2020-08-11 - SURFACE ONCOLOGY, INC. Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020

CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2020, ...

2019-09-08 - Surface Oncology Inc (NASDAQ:SURF) Short Interest Update

Surface Oncology Inc (NASDAQ:SURF) was the target of a large drop in short interest in the month of July. As of July 31st, there was short ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.6M484%N/A
#2
$3.7M48-21%$42M
#3
$7.4M4830%N/A
#4
$6.9M48N/AN/A
#5
$1.7M482%N/A

Surface Oncology Funding

DateAmountRoundLead InvestorsReference
2015-01-09$35.0MAMultipleArticle